Ipilimumab (CAS 477202-00-9) – Anti-CTLA-4 Monoclonal Antibody Anticancer API

Ipilimumab (CAS 477202-00-9) is a high-purity pharmaceutical API classified as a CTLA-4 inhibitor, featuring a recombinant fully human IgG1 kappa monoclonal antibody structure with a molecular weight of approximately 148 kDa. It specifically binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), blocking its interaction with CD80/CD86 ligands to release T-cell inhibition—activating anti-tumor immune responses and forming long-lasting immune memory. This premium API exhibits strong target affinity and stable bioactivity, ensuring consistent performance in injectable formulations.

It caters to the core needs of oncology drug manufacturers, biotech firms, and clinical research institutions. As a pioneering immune checkpoint inhibitor, it is widely applied in developing treatments for unresectable or metastatic melanoma, renal cell carcinoma, and malignant pleural mesothelioma. Produced under strict GMP-compliant biomanufacturing processes, each batch undergoes rigorous purity and potency testing to meet global biopharmaceutical standards. For businesses focusing on innovative immunotherapies, this Ipilimumab API serves as a critical raw material for advancing targeted anticancer therapy research and clinical applications.